PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。本研究不接受新入组。 （来自国家癌症研究所PDQ数据库的临床试验总结）化疗中使用的药物使用不同的方式来阻止肿瘤细胞分裂，使它们停止生长或死亡。联合使用一种以上的药物可以杀死更多的肿瘤细胞。 这是一项I/II期试验，旨在研究替莫唑胺联合伊立替康治疗复发性恶性胶质瘤患者的有效性。 患者将在第1-5天接受替莫唑胺口服给药，每天一次，并在第1天和第14天输注伊立替康。治疗可以每4周重复一次，持续长达1年。患者将每2个月接受一次随访评价，持续1年，每3个月接受一次随访评价，持续1年，每4个月接受一次随访评价，此后每4-6个月接受一次随访评价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to new enrollment. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. Patients will receive temozolomide by mouth once a day on Days 1-5 and an infusion of irinotecan on Days 1 and 14. Treatment may be repeated every 4 weeks for up to 1 year. Patients will receive follow-up evaluations every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, and every 4-6 months thereafter.